ArticlePakistan journal of medical sciences2026
Unraveling the molecular mechanisms in severe Alzheimer's disease based on transcriptomic data using next generation knowledge discovery methods.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objectives: Alzheimer's disease (AD) is characterized by gradual cognitive decline. Here, we deciphered the molecular mechanisms using transcriptomic data derived from the dorsolateral prefrontal cortex (DLPFC) of patients with severe AD using next-generation knowledge discovery (NGKD) techniques. Methodology: RNA sequencing data from the Gene Expression Omnibus (GEO) database (GSE53697) derived from the DLPFC of individuals with severe AD and healthy controls, obtained originally from frozen brain tissues of individuals classified based on the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria, and differentially expressed genes (DEGs) were identified by GEO2R analysis. The WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) was used for overrepresentation analysis (ORA) using the Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Database and Gene Set Enrichment Analysis (GSEA) using the KEGG, Reactome, and Wiki pathway databases. Ingenuity Pathway Analysis (IPA) software was used to decode the key canonical pathways and gene networks implicated in severe AD. Results: We identified 24,207 DEGs using P ≤0.05, and this list was further filtered with a fold change cut-off ±1.5 to derive 3103 genes. WebGestalt analysis showed that retrograde endocannabinoid signaling, motor proteins, oxidative phosphorylation, and ribosome biogenesis were downregulated, whereas pathways related to immune system activation, such as antigen processing and presentation and cytokine signaling, were enriched in patients with severe AD. IPA analysis showed significant downregulation of ribosomal RNA (rRNA) processing and enrichment of neuroinflammatory signaling pathways. Crucially, dysregulation of energy metabolism, protein synthesis, axonal transport, and immunological responses have been identified in the DLPFC of patients with severe AD. Conclusion: Using NGKD methods, we identified an array of molecular pathways implicated in neuroinflammation, dysregulation of energy metabolism, and mitochondrial damage in severe AD and their association with disease progression. Our findings add to the existing knowledge on the pathophysiology of severe AD and help in the development of more effective strategies for diagnosis, therapy, and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.